PLX51107 is a potent, selective BET bromodomain inhibitor with low nanomolar affinity for BRD2, BRD3, BRD4, and BRDT. This small molecule is a valuable research tool for investigating BET protein function in oncology, immunology, and inflammation, supporting both in vitro biochemical assays and in vivo preclinical studies.